Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 419-449 |
| Number of pages | 31 |
| Journal | Endocrine, Metabolic and Immune Disorders - Drug Targets |
| Volume | 18 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2018 |
Fingerprint
Cite this
Assessment of response to treatment and follow-up in gastroenteropancreatic neuroendocrine neoplasms. / Grimaldi, Franco; Fazio, N; Attanasio, Roberto; Frasoldati, A; Papini, Enrico; Cremonini, Nadia; Davì, MV; Funicelli, L; Massironi, S; Spada, F; Toscano, V; Versari, A; Zini, M; Falconi, M; Öberg, K.
In: Endocrine, Metabolic and Immune Disorders - Drug Targets, Vol. 18, No. 5, 2018, p. 419-449.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Assessment of response to treatment and follow-up in gastroenteropancreatic neuroendocrine neoplasms
AU - Grimaldi, Franco
AU - Fazio, N
AU - Attanasio, Roberto
AU - Frasoldati, A
AU - Papini, Enrico
AU - Cremonini, Nadia
AU - Davì, MV
AU - Funicelli, L
AU - Massironi, S
AU - Spada, F
AU - Toscano, V
AU - Versari, A
AU - Zini, M
AU - Falconi, M
AU - Öberg, K
PY - 2018
Y1 - 2018
N2 - Well-established criteria for evaluating the response to treatment and the appropriate follow-up of individual patients are critical in clinical oncology. The current evidence-based data on these issues in terms of the management of gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are unfortunately limited. This document by the Italian Association of Clinical Endocrinologists (AME) on the criteria for the follow-up of GEP-NEN patients is aimed at providing comprehensive recommendations for everyday clinical practice based on both the best available evidence and the combined opinion of an interdisciplinary panel of experts. The initial risk stratification of patients with NENs should be performed according to the grading, staging and functional status of the neoplasm and the presence of an inherited syndrome. The evaluation of response to the initial treatment, and to the subsequent therapies for disease progression or recurrence, should be based on a cost-effective, risk-effective and timely use of the appropriate diagnostic resources. A multidisciplinary evaluation of the response to the treatment is strongly recommended and, at every step in the follow-up, it is mandatory to assess the disease state and the patient performance status, comorbidities, and recent clinical evolution. Local expertise, available technical resources and the patient preferences should always be evaluated while planning the individual clinical management of GEP-NENs. © 2018 Bentham Science Publishers.
AB - Well-established criteria for evaluating the response to treatment and the appropriate follow-up of individual patients are critical in clinical oncology. The current evidence-based data on these issues in terms of the management of gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are unfortunately limited. This document by the Italian Association of Clinical Endocrinologists (AME) on the criteria for the follow-up of GEP-NEN patients is aimed at providing comprehensive recommendations for everyday clinical practice based on both the best available evidence and the combined opinion of an interdisciplinary panel of experts. The initial risk stratification of patients with NENs should be performed according to the grading, staging and functional status of the neoplasm and the presence of an inherited syndrome. The evaluation of response to the initial treatment, and to the subsequent therapies for disease progression or recurrence, should be based on a cost-effective, risk-effective and timely use of the appropriate diagnostic resources. A multidisciplinary evaluation of the response to the treatment is strongly recommended and, at every step in the follow-up, it is mandatory to assess the disease state and the patient performance status, comorbidities, and recent clinical evolution. Local expertise, available technical resources and the patient preferences should always be evaluated while planning the individual clinical management of GEP-NENs. © 2018 Bentham Science Publishers.
U2 - 10.2174/1871530318666171213145803
DO - 10.2174/1871530318666171213145803
M3 - Article
VL - 18
SP - 419
EP - 449
JO - Endocrine, Metabolic and Immune Disorders - Drug Targets
JF - Endocrine, Metabolic and Immune Disorders - Drug Targets
SN - 1871-5303
IS - 5
ER -